Adicet Bio Inc. (NASDAQ:ACET) traded with an addition of $0.03 to $1.77 on Thursday, an upside of 1.72 percent. An average of 706,063 shares of common stock have been traded in the last five days. There was a fall of -$0.2005 in the past week, and it reached a new high 12 times over the past 12 months. The last 20 days have seen an average of 526,391 shares traded, while the 50-day average volume stands at 1,064,162.
ACET stock has decreased by -29.76% in the last month. The company shares reached their 1-month lowest point of $1.7250 on 08/24/23. With the stock rallying to its 52-week high on 02/02/23, shares of the company touched a low of $1.73 and a high of $21.87 in 52 weeks. It has reached a new high 3 times so far this year and lost -80.20% or -$7.1705 in price. In spite of this, the price is down -91.91% from the 52-week high.
Insider Transactions
ACET stock investors should be aware that Adicet Bio Inc. (ACET) stock had its last reported insider trading activity 190 days ago on Jun 30. In this transaction, the insider spent $34,327. Chief Technology Officer, Healey Don, disposed of 10,467 shares at a price of $7.98 on Feb 10. The insider now owns more than $83,476 worth of shares. Prior to that, President & CEO Schor Chen went on to Sale 30,000 shares at $20.06 each on Nov 10. An amount of $601,920 was transacted.
Valuation Metrics
Adicet Bio Inc. (ACETstock’s beta is 1.99. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.32.
Financial Health
The quick ratio of Adicet Bio Inc. for the three months ended June 29 was 11.10, and the current ratio was 11.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Adicet Bio Inc.’s EBITDA margin for the year ending June 29 is -270.28%. Its gross profit as reported stood at $97.54 million compared to revenue of $24.99 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Adicet Bio Inc.’s return on assets was -36.30%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$32.4 million in the quarter, while revenues were grew 30.43%. The analyst consensus anticipated Adicet Bio Inc.’s latest quarter earnings to come in at -$0.68 per share, but it turned out to be -$0.75, a -10.30% surprise. For the quarter, EBITDA amounted to -$33.37 million. Shareholders own equity worth $43.07 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Adicet Bio Inc. (ACET) price momentum. RSI 9-day as of the close on 23 August was 24.86%, suggesting the stock is oversold, with historical volatility in this time frame at 40.60%.
As of today, ACET’s price is $1.8099 -10.18% or -$0.2005 from its 5-day moving average. ACET is currently trading -29.22% lower than its 20-day SMA and -69.28% lower than its 100-day SMA. However, the stock’s current price level is -63.29% below the SMA50 and -90.10% below the SMA200.
The stochastic %K and %D were 2.95% and 2.90%, respectively, and the average true range (ATR) was 0.1650. With the 14-day stochastic at 6.22% and the average true range at 0.1975, the RSI (14) stands at 28.64%. The stock has reached -0.1646 on the 9-day MACD Oscillator while the 14-day reading was at -0.2754.
Analyst Ratings
JMP Securities downgraded Adicet Bio Inc. (NASDAQ: ACET) to a a Mkt perform rating in its most recent analyst report. Previously, the stock was rated as a Mkt outperform. The consensus rating for Adicet Bio Inc. (ACET) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ACET, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is ACET’s price target for the next 12 months?
Analysts predict a range of price targets between $10.00 and $28.00, with a median target of $25.00. Taking a look at these predictions, the average price target given by analysts for Adicet Bio Inc. (ACET) stock is $21.00.
